Table 2

Study characteristics

Study or subgroup (reference)InclusionTerminology (REF)NInterventionOutcomeEvaluation Time of outcome
Bos et al 200931 Arthralgia without synovitis(d)83Dexamethasone 100 mg IM, W0 and W6
  • RA occurrence

  • W52 and more (mean duration of follow-up: 52.5 months)

Gerlag et al 2016 (PRAIRI)26 Arthralgia without synovitis(d)81RTX 1000 mg J0
  • RA occurrence

  • 29 months

Verstappen et al 2009 (STIVEA)21 UA ACPA/RF+naive of treatment(e)22480 mg MP
W0-1-2
  • DAS

  • HAQ

  • Radiographic score

  • RA occurrence*

  • Baseline, W24, 52

  • Baseline, W52

  • W52

  • W52

Machold et al 2009 (SAVE)22 UA ACPA/RF +
Naive
(e)303120 mg MP J0
  • DAS

  • RA occurrence

  • Baseline, W12, W52

  • 12 months

van Dongen et al 2007 (PROMPT)16 UA ACPA/RF +
GC allowed
(e)55MTX until 30 mg/wk
  • DAS

  • Radiographic score

  • RA occurrence

  • Baseline, W12, W52

  • Baseline, M18

  • 30 months, 60 months

Saleem et al 200823 UA ACPA/RF +
GC allowed
(e)17INF 3 mg/kg
W0-2-4-6-14
  • DAS

  • HAQ

  • Radiographic score

  • RA occurrence

  • Baseline, W12, 24

  • Baseline, W12, 24,

  • W52

  • W52

Durez 201132 UA ACPA +(e)30INF
3 mg/kg
W0, 2, 6, 14, 22
  • RA occurrence

  • DAS28

  • ACR 20 −50–70

  • 12 months

  • W52

  • W14

Nam et al 2013 (EMPIRE)25 UA ACPA/RF +
GC allowed
(e)82ETN50 mg/wk+MTX
  • DAS

  • HAQ

  • Radiographic score

  • RA occurrence

  • Baseline, W12, W52, M18

  • Baseline, W52, M18

  • Baseline, W52, M18

  • 12 months

Emery et al 2009 (ADJUST)24 UA ACPA/RF+or VERA
GC allowed (<10 mg/day)
(e) or (f)11ABA 100 mg/kg
Day: 1-15-29-57-85-113-141-169
  • DAS

  • Radiographic score

  • HAQ

  • RA occurrence

  • Baseline, W24, 52

  • Baseline, W52

  • Baseline

  • 6 months

Emery et al 2011 (COMET) post hoc27 VERA(f)112MTX vs MTX+ETN 50 mg/wk
  • DAS28

  • Radiographic score

  • W52

  • Baseline, W52

  • RA occurrence: according to ACR 1987 for all studies except for PRAIRI and STIVEA which correspond to the rheumatologist’s opinion.

  • (*a) genetic risk factor of RA; (b) environmental risk factor of RA; (c) systemic auto-immunity associated with RA; (d) symptoms without clinical arthritis; (e) UA; (f) RA (according EULAR 2012 recommendations for terminology12).

  • ABA, abatacept; ACPA, anticitrullinated protein antibody; ACR, DAS, disease activity score; ETN, etanercept; GC, glucocorticoids; HAQ, health assessment questionnaire; INF, infliximab; MP, methylprednisolone; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor;  RTX, rituximab; UA, unclassified arthritis (ie, patients presenting arthritis and ultrasound-detected synovitis, without ACPA or RF positivity); VeRA (ie, patients with clinical arthritis evolving for <16 weeks and fulfilling the 2010 ACR/EULAR criteria but not the 1987 ACR criteria); W, week.